More recently, evidence has shown that lymphatic dysfunction associated with inactivation of VEGFR-3, which is classically associated with lymphedema in Milroy’s disease (Butler et al., 2007), is linked to the pathogenesis of obesity and adipose tissue accumulation (Rutkowski et al., 2010) and that targeting this signaling pathway to improve lymphatic function may provide resolution of metabolic syndrome. The gene discussed is FLT4; the disease is lymphedema.